

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Multiple Myeloma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following survival outcomes was reported in the Phase III PERSEUS trial of subcutaneous daratumumab in combination with RVD versus RVD, each as induction therapy followed by lenalidomide maintenance, for transplant-eligible patients with newly diagnosed multiple myeloma (MM)?**
 - a. No significant improvement in progression-free survival (PFS) or overall survival (OS)
 - b. Significant improvement in PFS with a favorable trend toward improved OS**
 - c. Significant improvement in PFS and OS
- 2. Incidence of which of the following adverse events was significantly reduced with the addition of selinexor to bortezomib/dexamethasone for patients with relapsed/refractory (R/R) MM in the BOSTON trial?**
 - a. Thrombocytopenia
 - b. Peripheral neuropathy**
 - c. Cataracts
 - d. Fatigue
- 3. What is the optimal approach to antiemetic prophylaxis for patients receiving selinexor?**
 - a. No antiemetic prophylaxis is required; administer antiemetics only after symptoms occur
 - b. Ondansetron before starting therapy and during treatment
 - c. Dual antiemetic prophylaxis before starting therapy and during treatment**
- 4. In the Phase III CARTITUDE-4 trial, ciltacabtagene autoleucel yielded which of the following outcomes in comparison to physician's choice of pomalidomide/bortezomib/dexamethasone or daratumumab/pomalidomide/dexamethasone for patients with R/R MM who had received at least 1 prior line of therapy and whose disease was refractory to lenalidomide?**
 - a. No difference in OS
 - b. A numerical but nonsignificant trend in improved OS
 - c. A statistically significant improvement in OS**
- 5. Recently presented updated efficacy outcomes from the Phase III DREAMM-7 trial yielded which of the following outcomes with belantamab mafodotin/ bortezomib/dexamethasone when compared to daratumumab/bortezomib/dexamethasone for patients with R/R MM who had received at least 1 prior line of therapy?**
 - a. No difference in OS
 - b. A numerical but nonsignificant trend in improved OS
 - c. A statistically significant improvement in OS**